Basic Information
OCTREOSCAN FOR INJECTION
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN11244P
December 16, 1999
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 4, 2025
Company Information
Active Ingredients
Strength: 10 mcg/vial (in vial B)
Strength: 122 MBq/1.1 ml (in vial A)
Detailed Information
Contraindications
**III. Contraindications** No specific contraindications have been identified.
Indication Information
**I. Indications** 111In pentetreotide specifically binds to receptors for somatostatin. OctreoScan is indicated for use as adjunct in the diagnosis and management of receptor bearing gastro-entero-pancreatic neuroendocrine (GEP) tumours and carcinoid tumours, by aiding in their localisation. Tumours which do not bear receptors will not be visualised. In a number of patients suffering from GEP or carcinoid tumours the receptor density is insufficient to allow visualisation with OctreoScan. Notably in approximately 50% of patients suffering from insulinoma the tumour cannot be visualised.